Indication
NK/T-cell lymphoma
2 clinical trials
2 products
Clinical trial
An Open, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLStatus: Recruiting, Estimated PCD: 2025-02-01
Product
GNC-038Clinical trial
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)Status: Recruiting, Estimated PCD: 2024-06-15
Product
Brentuximab vedotin